Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

ClinicalTrials.gov ID: NCT00490516

Public ClinicalTrials.gov record NCT00490516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study of the Efficacy and Safety of ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.

Study identification

NCT ID
NCT00490516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Enrollment
247 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 60 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2007
Primary completion
Jan 31, 2008
Completion
Jan 31, 2008
Last update posted
Jan 19, 2025

2007 – 2008

United States locations

U.S. sites
21
U.S. states
8
U.S. cities
21
Facility City State ZIP Site status
Not listed Anaheim California 92805
Not listed Costa Mesa California 92626
Not listed Covina California 91724
Not listed Culver City California 90232
Not listed Garden Grove California 92845
Not listed Glendale California 91206
Not listed Huntington Beach California 92647
Not listed Oceanside California 92056
Not listed Paramount California 90723
Not listed Pasadena California 91107
Not listed Pico Rivera California 90660
Not listed Riverside California 92506
Not listed San Diego California 92108
Not listed Bradenton Florida 34208
Not listed Kissimmee Florida 34741
Not listed Atlanta Georgia 30308
Not listed Baltimore Maryland 21202
Not listed St Louis Missouri 63118
Not listed Willingboro New Jersey 08046
Not listed Philadelphia Pennsylvania 19139
Not listed Austin Texas 78754

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated Schizophrenia trials

Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.

All Schizophrenia trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00490516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2025 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00490516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →